A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma
Listen to this summary
The authors investigate the biological basis of primary refractoriness (PRef) to the combination of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC), aiming to identify immunological characteristics that distinguish non-responding patients. They find that PRef is associated with a distinct immunosuppressive tumor microenvironment, characterized by myeloid infiltration and systemic inflammation, which may inform future strategies to enhance treatment efficacy. The study highlights the need for biomarker-driven approaches to address the approximately 40% of patients who experience early treatment failure.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Journal of hepatology
View all →Jun 24, 2026 · Journal of hepatology
Regression of liver cirrhosis
Jun 22, 2026 · Journal of hepatology
The Hepato-Exposome Axis: How Endocrine Disruptors Hijack Liver Receptors to Drive MASLD
Jun 22, 2026 · Journal of hepatology
Hepatic artery infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: Pooled individual patient-level analysis of four clinical trials
Jun 20, 2026 · Journal of hepatology
MRI-based prediction of very early recurrence within 1 year after resection of HCC: An international cohort study
Jun 18, 2026 · Journal of hepatology
Interleukin-19 ameliorates drug-induced liver injury by limiting proinflammatory macrophage infiltration via SUMOylation of C/EBPβ
Jun 17, 2026 · Journal of hepatology
Impaired glycoRNA biogenesis in metabolic-dysfunction associated steatotic liver disease
More in Internal Medicine
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
